A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance
Junfeng Xia , Peilin Jia , Katherine E. Hutchinson , Kimberly B. Dahlman
Molecular Cancer Therapeutics 13 ( 7) 1918 -1928
105
2014
MSEA: detection and quantification of mutation hotspots through mutation set enrichment analysis
Peilin Jia , Quan Wang , Qingxia Chen , Katherine E Hutchinson
Genome Biology 15 ( 10) 489 -489
32
2014
BAC Consensus Conference, November 4–6, 2004: Epidemiology, Pathogenesis, and Preclinical Models
David C. Christiani , William Pao , James C. DeMartini , R Ilona Linnoila
Journal of Thoracic Oncology 1 ( 9) S2 -S7
16
2006
Monitoring EGFR-Mutant Lung Cancers By Means of the Blood
William Pao
Journal of Thoracic Oncology 1 ( 3) 199 -200
1
2006
Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.
Wee-Lee Yeo , Gregory J. Riely , Beow Y. Yeap , Michelle W. Lau
Journal of Thoracic Oncology 5 ( 7) 1048 -1053
86
2010
Spectrum of LKB1, EGFR, and KRAS Mutations in Chinese Lung Adenocarcinomas
Bin Gao , Yihua Sun , Junhua Zhang , Yan Ren
Journal of Thoracic Oncology 5 ( 8) 1130 -1135
106
2010
Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer
Katharine A. Price , Christopher G. Azzoli , Lee M. Krug , Maria C. Pietanza
Journal of Thoracic Oncology 5 ( 10) 1623 -1629
95
2010
Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations
Yelena Y Janjigian , Bernard J Park , Maureen F Zakowski , Marc Ladanyi
Journal of Thoracic Oncology 6 ( 3) 569 -575
149
2011
T4 or MI?
Salyka Sengsayadeth , Jay Montgomery , William Pao
Journal of Thoracic Oncology 6 ( 3) 632
2011
Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib.
Melissa L. Johnson , Greg J. Riely , Naiyer A. Rizvi , Christopher G. Azzoli
Journal of Thoracic Oncology 6 ( 6) 1128 -1131
60
2011
A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations
Gregory J. Riely , Melissa L. Johnson , Chanoa Medina , Naiyer A. Rizvi
Journal of Thoracic Oncology 6 ( 8) 1435 -1437
99
2011
Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains
Chenguang Li , Yihua Sun , Rong Fang , Xiangkun Han
Journal of Thoracic Oncology 7 ( 1) 85 -89
101
2012
EGFR-Mutant Lung Adenocarcinomas Treated First-Line with the Novel EGFR Inhibitor, XL647, Can Subsequently Retain Moderate Sensitivity to Erlotinib
Juliann Chmielecki , M. Catherine Pietanza , Dana Aftab , Ronglai Shen
Journal of Thoracic Oncology 7 ( 2) 434 -442
15
2012
Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping
Geoffrey R. Oxnard , Vincent A. Miller , Mark E. Robson , Christopher G. Azzoli
Journal of Thoracic Oncology 7 ( 6) 1049 -1052
77
2012
Encouragement to submit data of clinical response to EGFR-TKIs in patients with uncommon EGFR mutations.
Yasushi Yatabe , William Pao , James R. Jett
Journal of Thoracic Oncology 7 ( 5) 775 -776
19
2012
Effects of Pharmacokinetic Processes and Varied Dosing Schedules on the Dynamics of Acquired Resistance to Erlotinib in EGFR-Mutant Lung Cancer
Jasmine Foo , Juliann Chmielecki , William Pao , Franziska Michor
Journal of Thoracic Oncology 7 ( 10) 1583 -1593
64
2012
Further Advances in Genetically Informed Lung Cancer Medicine
Caroline Nebhan , William Pao
Journal of Thoracic Oncology 8 ( 5) 521 -522
2
2013
Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas.
Rui Wang , Yunjian Pan , Chenguang Li , Huibiao Zhang
Journal of Thoracic Oncology 9 ( 6) 760 -768
40
2014
Rational, biologically based treatment of EGFR -mutant non-small-cell lung cancer
William Pao , Juliann Chmielecki
Nature Reviews Cancer 10 ( 11) 760 -774
1,122
2010
Inconsistency and features of single nucleotide variants detected in whole exome sequencing versus transcriptome sequencing: A case study in lung cancer
Timothy D. O’Brien , Peilin Jia , Junfeng Xia , Uma Saxena
Methods 83 118 -127
21
2015